We also describe the effects of INX-315 in preclinical models of CCNE1-amplified cancer and use the compound to dissect out the roles of CDK2 and CDK4/6 in treatment-naïve and therapy-resistant luminal breast cancers. Here, CDK2 is linked to breast carcinoma.